CSL Canada Announces First Canadian Patient Receives HEMGENIX® Hemophilia B Gene Therapy in Ontario, Canada
Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® Over Five Years
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance for Public Reimbursement of HEMGENIX® , the First Gene Therapy for Hemophilia B
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
SAGA Metals Completes Acquisition of Wolverine Heavy Rare Earth Element Project in Labrador-REE Mineralized Potential Similar to Strange Lake and Tanbreez
Golconda Gold Releases Q2 2026 Production Update at Galaxy And Announces Mobilisation of Mining Contractor at Summit
